Inventage Lab, a drug delivery platform company, has secured substantial funding to bolster its operations. The company, which develops long-acting injectable formulations using its drug delivery system (DDS) platform technology, plans to accelerate its business by investing in research and development (R&D), operational costs, and Good Manufacturing Practice (GMP) facilities.
Industry sources reported on Tuesday that Inventage Lab successfully raised 985 billion KRW (approximately 667 million USD). The company initially aimed for 800 billion KRW (approximately 542 million USD) but surpassed its target by 123% due to high interest from institutional investors, smoothly completing a funding round that approached 1 trillion KRW (approximately 677 million USD).
Many existing investors who had participated in pre-initial public offering (IPO) and post-IPO mezzanine investments re-engaged in this funding round. Industry experts view this as a strong vote of confidence in the company’s platform technology and business potential.
Inventage Lab has developed a DDS platform capable of high-quality mass production and is working on improved new drugs. Their key products include the long-acting injectable platform IVL-DrugFluidic and the subcutaneous injection (SC) formulation platform for biopharmaceuticals, IVL-BioFluidic. This significant funding is expected to enhance production capacity and speed up commercialization efforts.
The company is poised to expand its capabilities in developing and producing genetic material-based formulations, such as Messenger Ribonucleic Acid (mRNA), Plasmid DNA (pDNA), and Lipid Nanoparticles (LNP), moving beyond traditional peptide and small molecule-based DDS.
After acquiring Quratis, a vaccine development and contract development manufacturing organization (CDMO), early last year, Inventage Lab secured GMP manufacturing facilities. The new funding is set to further propel the global commercialization of its long-acting injectable platform.
An industry insider predicts that as the DDS market is projected to grow at an average annual rate of 4.1%, reaching 63.38 billion USD by 2032, Inventage Lab’s enhanced commercialization production system could attract increased attention from global pharmaceutical companies.
Expanding Long-Acting Injectables to Treat Obesity and Hair Loss
Inventage Lab is simultaneously developing treatments for obesity, dementia, and hair loss, aiming to broaden its therapeutic reach.
Earlier this year, the company secured a domestic patent for its technology that reformulates Orforglipron, a promising small molecule compound for obesity and diabetes treatment, into a long-acting injectable.
In collaboration with Yuhan Corporation, Inventage Lab has identified the final candidate for YHP2402, a long-acting injectable formulation of semaglutide for obesity treatment, and is preparing for clinical sample production.
The patent’s core innovation lies in precise initial release control. By reducing the initial release rate according to strict criteria, the formulation aims to minimize gastrointestinal side effects associated with rapid drug concentration increases typical of oral medications.
Additionally, the formulation enhances bioavailability, ensuring stable long-term therapeutic effects while addressing the limitations of existing oral medications.
Inventage Lab plans to initiate entry procedures in key global markets including the U.S., Europe, and Japan to secure worldwide rights.
Chief Executive Officer (CEO) Kim Joo-hee stated that its core patents and this first registration for Orforglipron demonstrate Inventage Lab’s leading position in developing long-acting formulations for obesity treatment. It will continue to strengthen the capabilities in long-acting injectable formulations for various peptide and small molecule-based treatments targeting obesity and metabolic diseases.
